<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149671">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901588</url>
  </required_header>
  <id_info>
    <org_study_id>S12-00556</org_study_id>
    <nct_id>NCT01901588</nct_id>
  </id_info>
  <brief_title>Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery</brief_title>
  <official_title>Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is trying to see if using precedex pre-operatively prevents emergence delirium in
      pediatric (ages 1-7) patients undergoing strabismus surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emergence delirium (ED) is a complex behavioral disturbance characterized by psychomotor
      agitation, perceptual disturbances, delusions, and disorientation during recovery from
      general anesthesia. In the population of subjects who undergo strabismus surgery, there are
      multiple factors that may increase the risk of ED. These include age, typically preschool
      children aged 1-7 years, rapid surgical times with rapid awakening, use of sevoflurane as
      the primary anesthetic, and surgically-induced postoperative visual disturbance. The aims of
      this study are: 1) To examine whether post-induction treatment with an α-2 receptor agonist,
      precedex (dexmedetomidine), decreases postoperative emergence agitation after strabismus
      surgery compared to placebo, and 2) to determine whether treatment has any effect on
      postoperative pain, nausea/vomiting, number of pain-related interventions, and time to PACU
      discharge. We hypothesize that precedex  will attenuate the ED response greater than placebo
      or a lower dose after strabismus surgery and will reduce PACU pain scores without increasing
      PACU length of stay.

      Inclusion:

      i. Pediatric patients aged 1-7 years of age ii. ASA physical status I-II iii. No significant
      laboratory abnormalities

      Exclusion:

      i. Presence of medicated behavioral disorder ii. Subjects for which precedex, opiates,
      benzodiazepines, or inhalational anesthetics are contraindicated iii. Parental refusal
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Efficacy of Single-Shot Dexmedetomidine versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery</measure>
    <time_frame>two years</time_frame>
    <safety_issue>No</safety_issue>
    <description>To examine whether post-induction treatment with an α-2 receptor agonist, dexmedetomidine, decreases postoperative emergence agitation after strabismus surgery compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post operative interventions</measure>
    <time_frame>4 hours after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>to determine whether treatment has any effect on postoperative pain, nausea/vomiting, number of pain-related interventions, and time to PACU discharge</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Strabismus</condition>
  <condition>Delirium on Emergence</condition>
  <condition>Pediatric Disorders</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine/precedex</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients receive saline solution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intraoperative dose of intravenous placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA physical status of I or II

          -  male or female, aged 1-7

          -  has no significant lab abnormalities

        Exclusion Criteria:

          -  ASA physical status of III, IV or V

          -  Presence of medicated behavioral disorder

          -  Subjects for which dexmedetomidine, opiates, benzodiazepines or inhalational
             anesthetics are contraindicated.

          -  Parental refusal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lola Franco, BA</last_name>
    <phone>212.263.0531</phone>
    <email>lola.franco@nyumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annelise E von Bergen Granell, BS, MS</last_name>
    <phone>212.263.0667</phone>
    <email>annelise.vonbergengranell@nyumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason Brown, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gordana Stjepanovic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Steele, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer McGrath, BA, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lola Franco, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annelise E von Bergen Granell, BS, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Avri Bohm, BA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sorosch Didehvar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manit Roy, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Haile, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wanda Chin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 26, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York University School of Medicine</investigator_affiliation>
    <investigator_full_name>Wanda Chin</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>strabismus</keyword>
  <keyword>pediatric</keyword>
  <keyword>emergence delirium</keyword>
  <keyword>precedex/dexmedetomidine</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Strabismus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
